Pipeline
Drugging the “Undruggable”
Canonical disease drivers, but have not been drugged
Improved Drugs for Validated Targets
Improved selectivity or drug characteristics vs available therapeutics
Genetic
Diseases
Well-understood biology
Novel
Targets
Leverage the power and scale of academic collaborations to explore novel biology
Our Pipeline
Each disease area and drug program in our pipeline takes us one step closer to transforming preclinical R&D using computational chemistry to discover small molecule drugs more efficiently than traditional approaches to deliver better medicines, faster.
Wholly Owned
Wholly Owned
Contact us to learn more about out-licensing our assets.
Disease Area
Target
Discovery
Optimization
Preclinical
Immunology
TYK2
Immunology
RIPK1
Immunology
RIPK2
15 Undisclosed
undisclosed
18 Undisclosed
undisclosed
Co-Developed
Co-Developed
Learn more about our growing portfolio companies.
Co-Development
Partner
Disease Area
Target
Discovery
Optimization
Preclinical
Oncology
PIM3
Oncology
SHP2
Hematology
Factor XII
Immunology
cGAS
Academic Collaborations
Academic Collaborations
Learn more about our research partnerships and biopharma partnerships.
Disease Areas
